The Emerging Role of M6A Modification in Endocrine Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 25

PMID 36831377

Authors

Xiaoyu Ji

Zhiyuan Wang

Wei Sun

Hao Zhang

Affiliations

Soon will be listed here.

Abstract

With the development of RNA modification research, N6-methyladenosine (m6A) is regarded as one of the most important internal epigenetic modifications of eukaryotic mRNA. It is also regulated by methylase, demethylase, and protein preferentially recognizing the m6A modification. This dynamic and reversible post-transcriptional RNA alteration has steadily become the focus of cancer research. It can increase tumor stem cell self-renewal and cell proliferation. The m6A-modified genes may be the primary focus for cancer breakthroughs. Although some endocrine cancers are rare, they may have a high mortality rate. As a result, it is critical to recognize the significance of endocrine cancers and identify new therapeutic targets that will aid in improving disease treatment and prognosis. We summarized the latest experimental progress in the m6A modification in endocrine cancers and proposed the m6A alteration as a potential diagnostic marker for endocrine malignancies.

Citing Articles

FTO/IGF2BP2-mediated N6 methyladenosine modification in invasion and metastasis of thyroid carcinoma via CDH12.

Chen Z, Zhong X, Xia M, Liu C, Tang W, Liu G Cell Death Dis. 2024; 15(10):733.

PMID: 39379360 PMC: 11461506. DOI: 10.1038/s41419-024-07097-4.

Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers.

Zhu D, Su K, Ou-Yang X, Zhang Y, Yu X, Li Z Mol Cell Biochem. 2024; 479(7):1553-1570.

PMID: 38856795 PMC: 11254988. DOI: 10.1007/s11010-024-05040-x.

References

Liu Y, Shi M, He X, Cao Y, Liu P, Li F . LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2022; 15(1):52. PMC: 9077921. DOI: 10.1186/s13045-022-01272-w. View

Knuckles P, Lence T, Haussmann I, Jacob D, Kreim N, Carl S . Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the mA machinery component Wtap/Fl(2)d. Genes Dev. 2018; 32(5-6):415-429. PMC: 5900714. DOI: 10.1101/gad.309146.117. View

Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y . FTO-Dependent -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling. Cancer Res. 2020; 80(16):3200-3214. PMC: 7442742. DOI: 10.1158/0008-5472.CAN-19-4044. View

Li X, Abdel-Mageed A, Kandil E . BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med. 2012; 5(4):310-5. PMC: 3443896. View

Wang Y, Chen Z . Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA. Bioengineered. 2021; 13(1):178-189. PMC: 8805991. DOI: 10.1080/21655979.2021.2011640. View

Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K . AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017; 7:42271. PMC: 5304225. DOI: 10.1038/srep42271. View

Li Y, Peng H, Jiang P, Zhang J, Zhao Y, Feng X . Downregulation of Methyltransferase-Like 14 Promotes Ovarian Cancer Cell Proliferation Through Stabilizing TROAP mRNA. Front Oncol. 2022; 12:824258. PMC: 8894193. DOI: 10.3389/fonc.2022.824258. View

Huang C, Zhou S, Zhang C, Jin Y, Xu G, Zhou L . ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Cancer Lett. 2022; 530:16-28. DOI: 10.1016/j.canlet.2022.01.013. View

Hsu P, Zhu Y, Ma H, Guo Y, Shi X, Liu Y . Ythdc2 is an N-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017; 27(9):1115-1127. PMC: 5587856. DOI: 10.1038/cr.2017.99. View

10.

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

11.

Chen J, Tao Y, Hong Y, Li H, Huang Z, Xu X . MA-mediated up-regulation of LncRNA LIFR-AS1 enhances the progression of pancreatic cancer via miRNA-150-5p/ VEGFA/Akt signaling. Cell Cycle. 2021; 20(23):2507-2518. PMC: 8794522. DOI: 10.1080/15384101.2021.1991122. View

12.

Tzelepis K, Rausch O, Kouzarides T . RNA-modifying enzymes and their function in a chromatin context. Nat Struct Mol Biol. 2019; 26(10):858-862. PMC: 7613430. DOI: 10.1038/s41594-019-0312-0. View

13.

Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F . Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014; 2(5):356-8. DOI: 10.1016/S2213-8587(13)70215-8. View

14.

He Y, Yue H, Cheng Y, Ding Z, Xu Z, Lv C . ALKBH5-mediated mA demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Cell Death Dis. 2021; 12(12):1121. PMC: 8636648. DOI: 10.1038/s41419-021-04401-4. View

15.

Hansen T, Batra S, Lim M, Gallia G, Burger P, Salvatori R . Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev. 2014; 37(2):279-85. PMC: 4322934. DOI: 10.1007/s10143-014-0525-y. View

16.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

17.

Li X, Abdel-Mageed A, Mondal D, Kandil E . The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers. Thyroid. 2013; 23(2):209-18. DOI: 10.1089/thy.2012.0237. View

18.

Li A, Chen Y, Ping X, Yang X, Xiao W, Yang Y . Cytoplasmic mA reader YTHDF3 promotes mRNA translation. Cell Res. 2017; 27(3):444-447. PMC: 5339832. DOI: 10.1038/cr.2017.10. View

19.

Nixon I, Simo R, Newbold K, Rinaldo A, Suarez C, Kowalski L . Management of Invasive Differentiated Thyroid Cancer. Thyroid. 2016; 26(9):1156-66. PMC: 5118958. DOI: 10.1089/thy.2016.0064. View

20.

Nie S, Zhang L, Liu J, Wan Y, Jiang Y, Yang J . ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021; 40(1):284. PMC: 8425158. DOI: 10.1186/s13046-021-02088-1. View